Klaria Pharma Holding AB (DE:6FN)
FRANKFURT:6FN
6FN Stock Chart & Stats
€0.06
>-€0.01(-25.00%)
At close: 4:00 PM EST
€0.06
>-€0.01(-25.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)8.58K
Market Cap
€21.44M
Enterprise Value€325.24M
Total Cash (Recent Filing)€342.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta2.44
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding245,976,150
10 Day Avg. Volume650
30 Day Avg. Volume8,579
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€2.22M
Bulls Say, Bears Say
Bulls Say
Proprietary Drug Delivery PlatformA proprietary mucoadhesive oral film platform is a durable competitive asset: it can enable differentiated formulations, easier patient adoption, and multiple product applications. If clinical and regulatory progress continues, the platform supports recurring licensing and product diversification over months to years.
Partnering/licensing StrategyAn explicit partnering and licensing strategy offers a structural, capital-efficient route to commercialization. By monetizing technology via partners, the company can transfer commercialization costs and leverage larger firms' scale, reducing cash burn and accelerating market access over the medium term.
Debt Reduced To Zero In 2025Eliminating reported debt materially lowers fixed financial obligations and interest sensitivity, improving solvency metrics and creditor flexibility. This structural improvement eases near-term liquidity pressure and expands options for equity, licensing, or non-debt financing over ensuing quarters.
Bears Say
Negative Shareholders' EquityNegative equity is a persistent fundamental weakness that constrains financing alternatives, increases likelihood of dilutive recapitalizations, and signals accumulated losses. Over 2–6 months this reduces creditworthiness and bargaining power with partners or lenders, limiting strategic flexibility.
Consistent Operating Cash BurnRepeated negative operating cash flow indicates the company cannot self-fund development and relies on external financing. Persistent cash burn raises dilution or financing risk, constrains R&D progression and trial funding, and is a durable headwind to executing on licensing or commercialization plans.
Severe Losses And Negative MarginsVery large negative margins reflect structural unprofitability and inability to convert revenue into earnings. Over the medium term this undermines sustainability, forces reliance on capital markets, and raises execution risk for scaling products even if technology and partnerships exist.
6FN FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was €0.03 and its highest was €0.12 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is €21.44M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is May 08, 2026 which is in 32 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on Feb 20, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6FN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.